A Phase I/II study to evaluate AZD5851 in GPC3+ advanced/recurrent hepatocellular carcinoma

Trial Identifier: D7670C00001
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: December 2027
Study Completion Date: December 2027
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 227-8577
JP Kyoto-shi, JP, 606-8507
JP Osakasayama-shi, JP, 589-8511
KR Seoul, KR, 03080
US, AZ Phoenix, AZ, US, 85054
US, CA Duarte, CA, US, 91010
US, CA Orange, CA, US, 92868
US, CA San Francisco, CA, US, 94143
US, DC Washington, DC, US, 20007
US, FL Jacksonville, FL, US, 32224
US, GA Atlanta, GA, US, 30322
US, KS Westwood, KS, US, 66205
US, MN Rochester, MN, US, 55905
US, NJ Hackensack, NJ, US, 07601
US, NY New York, NY, US, 10065
US, OH Columbus, OH, US, 43210
US, OR Portland, OR, US, 97239
US, PA Philadelphia, PA, US, 19104
US, PA Pittsburgh, PA, US, 15237